GSK Discontinues Camlipixant After Mixed Phase 3 Results in Chronic Cough
The company will continue developing the drug for irritable bowel syndrome (IBS).
/ 1648 items
#XY↓
Jasper Bolsters Pipeline with Kira Acquisition and $132 Million Private Placement
Combined company advances KP-104 and briquilimab with cash runway through H2 2028.
CareDx Shares Surge After Medicare Finalizes Transplant Testing Coverage
New policy brings clarity for kidney, heart, and lung patients.
Cash Constraints Force Wolfe to Downgrade Intellia to Underperform
Concerns over limited cash runway and slower clinical progress weigh on the stock.
Abbott Raises 2026 Outlook After Solid Q2 Beat Driven by Diagnostics and Devices
Abbott delivered robust Q2 2026 earnings driven by 42% growth in its Diagnostics segment, led by strong Cologuard adoption.
UnitedHealth Shares Surge as Q2 Results Top Forecasts and Guidance Raised
Strong cost control and Optum performance drive recovery.